Gossamer Hopes To Stand Out In Crowded Spaces
Executive Summary
The company plans to release topline results this year in ulcerative colitis and pulmonary arterial hypertension. In UC, especially, Gossamer is aiming for an opportunity that remains untapped.
You may also be interested in...
Bristol's High Profile TYK2 Inhibitor Disappoints In Ulcerative Colitis
Deucravacitinib is an oral drug in development for a wide range of autoimmune conditions, including psoriasis and psoriatic arthritis.
Rinvoq Shows Strong UC Efficacy, But Will JAK Ghosts Haunt It?
Safety appears balanced between the drug and placebo arms in upadacitinib’s third Phase III trial in ulcerative colitis, but there were low numbers of MACE and there are lingering safety concerns about the JAK class overall.
Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI
The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.